Daiichi Sankyo Co. Ltd. must follow patients on its new rare cancer treatment Turalio for at least a decade to determine whether there is a long-term risk of liver toxicity.
The US Food and Drug Administration on 2 August approved Turalio (pexidartinib) for treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations who are not amenable to improvement with